Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HRS-4642 + nalirifox + adebrelimab
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
HRS-4642 + nalirifox + adebrelimab is an investigational combination regimen being evaluated as a neoadjuvant therapy for pancreatic ductal adenocarcinoma (PDAC). The regimen consists of HRS-4642, a small molecule inhibitor targeting the KRAS G12D mutation; NALIRIFOX, a chemotherapy backbone comprising liposomal irinotecan, 5-fluorouracil, leucovorin, and oxaliplatin; and adebrelimab (SHR-1316), a monoclonal antibody that acts as a PD-L1 immune checkpoint inhibitor. Developed by Jiangsu Hengrui Pharmaceuticals, this combination therapy is designed to synergistically target oncogenic signaling, induce cytotoxic cell death, and enhance anti-tumor immune responses in patients with resectable or borderline-resectable PDAC.
- Other names
- HRS-4642 + NALIRIFOX + adebrelimabHRS-4642 + NALIRIFOX + SHR-1316
02
Targets
KRASG12D (Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutant)CD274 (Programmed cell death protein 1 ligand 1)TOP1 (DNA Topoisomerase I)TS (Thymidylate synthase)
Beyond the preview
Go deeper on HRS-4642 + nalirifox + adebrelimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HRS-4642 + nalirifox + adebrelimab.